Drugs / DLBS2411
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01573403 | Apr → Dec 2012 | — | Dexa Medica Group | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05248802 | Dec 2022 → Oct 2025 | dyspepsia | Dexa Medica Group | Completed | No outcome recorded |
| Phase 3 | NCT03367195 | Aug 2018 → May 2020 | gastroesophageal reflux disease | Dexa Medica Group | Terminated | No outcome recorded |
| Phase 3 | NCT02262169 | Oct 2014 → Feb 2019 | peptic ulcer disease | Dexa Medica Group | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DLBS2411 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02262169 ↗ |
| Action | Inhibit | “through the inhibition of H+/K+ ATPase 'pump'” NCT02262169 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “DLBS2411 is a bioactive fraction of an Indonesian native herbal, Cinnamomum burmanii” NCT02262169 ↗ |